Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report

被引:4
|
作者
Haider, Ahmad
Haider, Karim
Saad, Farid [1 ,2 ]
Hanefeld, Markolf [3 ]
机构
[1] Bayer AG, Global Med Affairs Androl, Muellerstr 178, D-13353 Berlin, Germany
[2] Gulf Med Univ, Sch Med, Ajman, U Arab Emirates
[3] GWT TUD GmbH, Studienzentrum Metabol Vaskulare Med, Dresden, Germany
来源
关键词
Testosterone therapy; type; 2; diabetes; late-onset" hypogonadism; obesity; cardiometabolic risk factors; HYPOGONADOTROPIC HYPOGONADISM; INSULIN-RESISTANCE; WEIGHT; MEN; OBESITY; MALES;
D O I
10.1177/2050313X18823454
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile dysfunction. He had type 2 diabetes, was overweight, and had hypertension and dyslipidemia. The blood test revealed testosterone deficiency. Under testosterone therapy, the patient lost 10 kg; cardiometabolic parameters returned to normal and lower urinary tract symptoms disappeared; complete remission of diabetes was recorded. Overweight and obese patients with type 2 diabetes should be tested for hypogonadism and testosterone therapy, if indicated, be considered. These patients can considerably benefit from testosterone therapy in terms of sustainable weight loss and a clinically significant reduction of cardiometabolic risk factors including complete remission of diabetes.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Long-term morbidity of late-onset hypogonadism
    Behre, HM
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (06) : 10 - 15
  • [2] LONG-TERM OUTCOMES OF TESTOSTERONE REPLACEMENT THERAPY FOR PATIENTS WITH LATE-ONSET HYPOGONADISM SYNDROME
    Ohira, S.
    Jo, T.
    Kakumae, S.
    Nakatsuka, T.
    Morinaka, H.
    Takasaki, H.
    Hirata, K.
    Sugiyama, S.
    Shimizu, S.
    Kaifu, M.
    Fujii, T.
    Miyaji, Y.
    Nagai, A.
    JOURNAL OF SEXUAL MEDICINE, 2022, 19 (05): : S176 - S176
  • [3] Testosterone treatment of late-onset hypogonadism – benefits and risks
    Peter Snyder
    Reviews in Endocrine and Metabolic Disorders, 2022, 23 : 1151 - 1157
  • [4] Long-term treatment with testosterone improves glycaemic control and may result in remission of diabetes in patients with hypogonadism and type 2 diabetes in a registry
    Penaherrera, N.
    Haider, K. S.
    Haider, A.
    Doros, G.
    Traish, A.
    Saad, F.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S307 - S308
  • [5] Testosterone treatment of late-onset hypogonadism - benefits and risks
    Snyder, Peter
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2022, 23 (06): : 1151 - 1157
  • [6] Late-onset Rasmussen's encephalitis and long-term remission
    Kupila, Laura
    Jutila, Leena
    Immonen, Arto
    Vanninen, Ritva
    Mervaala, Esa
    Pateau, Anders
    Luostarinen, Liisa
    Kalviainen, Reetta
    EPILEPTIC DISORDERS, 2011, 13 (01) : 88 - 91
  • [7] Remission of Type 2 Diabetes after Long-Term Testosterone Therapy
    Hanefeld, Markolf
    Haider, Ahmad
    Zitzmann, Michael
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (01): : 33 - 37
  • [8] Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus
    Arafa, M.
    Zohdy, W.
    Aboulsoud, S.
    Shamloul, R.
    ANDROLOGIA, 2012, 44 : 756 - 763
  • [9] LONG-ACTING INTRAMUSCULAR TESTOSTERONE UNDECANOATE FOR THE TREATMENT OF 118 LATE-ONSET HYPOGONADISM IN MALES
    Permpongkosol, Sompol
    Talubsri, Pungrudee
    JOURNAL OF UROLOGY, 2009, 181 (04): : 489 - 489
  • [10] Effect of testosterone replacement therapy on sarcopenia: Case report of an older man with late-onset hypogonadism
    Hosoi, Tatsuya
    Kojima, Taro
    Ishii, Shinya
    Ogawa, Sumito
    Akishita, Masahiro
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2020, 20 (01) : 85 - 86